Non-small cell lung cancer treatment
Research activity centers on non-small cell lung cancer (NSCLC), including unresectable, resectable, and completely resected disease, with attention to locally advanced and thoracic-confined tumors. The portfolio also includes ALK-positive and KRAS p.G12C disease, as well as upper-lobe and Pancoast presentations.
- Resectable and unresectable NSCLC
- ALK-positive lung cancer
- KRAS p.G12C-mutated NSCLC
- Thoracic-confined and completely resected disease
Clinical interests include perioperative, adjuvant, and maintenance therapy settings, with outcomes focused on progression-free survival, disease-free survival, and pathological complete response.
Immunotherapy and chemo-immunotherapy
The sponsor funds studies involving immune checkpoint inhibitors and combination regimens across multiple lung cancer settings, including first-line treatment, post-chemoradiotherapy maintenance, and treatment after surgery. Agents studied include atezolizumab, cemiplimab, pembrolizumab, nivolumab, and ipilimumab.
- Checkpoint inhibitor combinations
- First-line immunotherapy-based treatment
- Adjuvant and maintenance immunotherapy
- Chemo-immunotherapy in resectable disease
Several trials address treatment selection in PD-L1-expressing disease and compare immunotherapy-based approaches with chemotherapy-alone strategies.
Small cell lung cancer and extensive-stage disease
Research also covers small cell lung cancer (SCLC), including extensive-stage SCLC and settings after chemoradiotherapy. The portfolio includes maintenance-focused approaches and combination strategies for patients with advanced thoracic malignancy.
- Extensive-stage SCLC
- Post-chemoradiotherapy maintenance
- Advanced lung cancer combination therapy
- Thoracic disease control
Therapeutic interest extends to tarlatamab and other regimens evaluated for disease control in advanced small cell lung cancer.
Brain metastasis and advanced metastatic disease
Some studies focus on non-small cell lung cancer with brain metastasis and other advanced metastatic presentations, reflecting interest in disease control beyond the primary thoracic site. These trials examine systemic treatment strategies for patients with central nervous system involvement.
- Brain metastases in lung cancer
- Metastatic NSCLC
- Intracranial disease control
- Systemic therapy for advanced spread
Clinical endpoints include intracranial clinical benefit and broader measures of tumor response in metastatic settings.
Biomarker-guided and targeted approaches
The sponsor supports trials using circulating tumor DNA to guide treatment decisions and studies of targeted agents in molecularly defined lung cancer. This includes research in patients selected by tumor biology and blood-based markers.
- ctDNA-guided treatment selection
- Molecularly defined lung cancer
- Targeted therapy in ALK and KRAS alterations
- Blood-based monitoring strategies
Therapeutic interest includes brigatinib, sotorasib, and biomarker-informed use of cemiplimab in lung cancer management.
